Published in Anticancer Agents Med Chem on September 01, 2006
Cooperation between integrin alphavbeta3 and VEGFR2 in angiogenesis. Angiogenesis (2009) 1.58
18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging (2007) 1.49
Integrin targeting for tumor optical imaging. Theranostics (2011) 1.47
Molecular imaging and therapy of cancer with radiolabeled nanoparticles. Nano Today (2009) 1.47
Integrin targeted delivery of chemotherapeutics. Theranostics (2011) 1.42
Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology (2009) 1.39
Noninvasive imaging of tumor integrin expression using (18)F-labeled RGD dimer peptide with PEG (4) linkers. Eur J Nucl Med Mol Imaging (2009) 1.35
Podocyte biology and pathogenesis of kidney disease. Annu Rev Med (2012) 1.32
Are quantum dots ready for in vivo imaging in human subjects? Nanoscale Res Lett (2007) 1.30
Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol (2009) 1.27
Molecular ultrasound assessment of tumor angiogenesis. Angiogenesis (2010) 1.26
Molecular imaging in cancer treatment. Eur J Nucl Med Mol Imaging (2010) 1.21
Integrin alpha(v)beta(3)-Targeted Cancer Therapy. Drug Dev Res (2008) 1.17
Impact of tumor microenvironment on oncolytic viral therapy. Cytokine Growth Factor Rev (2010) 1.13
Positron emission tomography imaging of prostate cancer. Amino Acids (2009) 1.11
Multimodality Imaging of Integrin α(v)β(3) Expression. Theranostics (2011) 1.10
CD23/FcεRII: molecular multi-tasking. Clin Exp Immunol (2010) 1.10
αVβ3 integrin regulates macrophage inflammatory responses via PI3 kinase/Akt-dependent NF-κB activation. J Cell Physiol (2011) 1.09
PAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma. Bioconjug Chem (2009) 1.08
Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets (2010) 1.07
Positron emission tomography imaging of cancer biology: current status and future prospects. Semin Oncol (2011) 1.02
Optical imaging of integrin alphavbeta3 expression with near-infrared fluorescent RGD dimer with tetra(ethylene glycol) linkers. Mol Imaging (2010) 1.01
Imaging of tumor angiogenesis: functional or targeted? AJR Am J Roentgenol (2009) 1.00
Cancer-targeted optical imaging with fluorescent zinc oxide nanowires. Nano Lett (2011) 1.00
Galphas-coupled receptor signaling actively down-regulates alpha4beta1-integrin affinity: a possible mechanism for cell de-adhesion. BMC Immunol (2008) 0.99
Photoacoustic imaging. Cold Spring Harb Protoc (2011) 0.96
Crosstalk between integrin αvβ3 and estrogen receptor-α is involved in thyroid hormone-induced proliferation in human lung carcinoma cells. PLoS One (2011) 0.96
Nanotheranostics for personalized medicine. Expert Rev Mol Diagn (2013) 0.96
Molecular Imaging with Single-Walled Carbon Nanotubes. Nano Today (2009) 0.95
Imaging with Raman spectroscopy. Curr Pharm Biotechnol (2010) 0.94
PET Imaging of Angiogenesis. PET Clin (2009) 0.94
Integrin alpha9beta1: Unique signaling pathways reveal diverse biological roles. Cell Adh Migr (2010) 0.93
Nanotherapeutics in angiogenesis: synthesis and in vivo assessment of drug efficacy and biocompatibility in zebrafish embryos. Int J Nanomedicine (2011) 0.91
Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-αvβ3 integrin complex in tumorigenesis and angiogenesis. FEBS J (2013) 0.91
Non-invasive imaging of human embryonic stem cells. Curr Pharm Biotechnol (2010) 0.91
Integrin αvβ3-targeted gold nanoshells augment tumor vasculature-specific imaging and therapy. Int J Nanomedicine (2011) 0.91
Radiolabeled γ-AApeptides: a new class of tracers for positron emission tomography. Chem Commun (Camb) (2012) 0.90
PET imaging of acute and chronic inflammation in living mice. Eur J Nucl Med Mol Imaging (2007) 0.90
Multi-functional self-fluorescent unimolecular micelles for tumor-targeted drug delivery and bioimaging. Biomaterials (2015) 0.89
Antibody drug-conjugates targeting the tumor vasculature: Current and future developments. MAbs (2010) 0.88
Specific targeting of human integrin α(v)β (3) with (111)In-labeled Abegrin™ in nude mouse models. Mol Imaging Biol (2011) 0.87
Decellularized matrix from tumorigenic human mesenchymal stem cells promotes neovascularization with galectin-1 dependent endothelial interaction. PLoS One (2011) 0.85
Radionuclide-Based Cancer Imaging Targeting the Carcinoembryonic Antigen. Biomark Insights (2008) 0.84
Targeting activated integrin alphavbeta3 with patient-derived antibodies impacts late-stage multiorgan metastasis. Clin Exp Metastasis (2010) 0.83
Biomedical applications of zinc oxide nanomaterials. Curr Mol Med (2013) 0.83
Preclinical molecular imaging of tumor angiogenesis. Q J Nucl Med Mol Imaging (2010) 0.83
Production and characterization of a humanized single-chain antibody against human integrin alphav beta3 protein. J Biol Chem (2011) 0.82
Nitric oxide/cGMP pathway signaling actively down-regulates α4β1-integrin affinity: an unexpected mechanism for inducing cell de-adhesion. BMC Immunol (2011) 0.82
Applications of molecular imaging. Prog Mol Biol Transl Sci (2010) 0.81
Protein-based tumor molecular imaging probes. Amino Acids (2010) 0.81
Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery. Int J Cancer (2013) 0.80
Molecular magnetic resonance contrast agents for the detection of cancer: past and present. Semin Oncol (2011) 0.80
Targeted Cancer Therapy with Tumor Necrosis Factor-Alpha. Biochem Insights (2008) 0.79
γ-AApeptides: Design, Structure, and Applications. Acc Chem Res (2016) 0.79
Immunohistochemical analysis of integrins αvβ3, αvβ5 and α5β1, and their ligands, fibrinogen, fibronectin, osteopontin and vitronectin, in frozen sections of human oral head and neck squamous cell carcinomas. Exp Ther Med (2010) 0.78
A novel dendritic nanocarrier of polyamidoamine-polyethylene glycol-cyclic RGD for "smart" small interfering RNA delivery and in vitro antitumor effects by human ether-à-go-go-related gene silencing in anaplastic thyroid carcinoma cells. Int J Nanomedicine (2013) 0.78
In Vivo Biodistribution and Anti-Tumor Efficacy Evaluation of Doxorubicin and Paclitaxel-Loaded Pluronic Micelles Decorated with c(RGDyK) Peptide. PLoS One (2016) 0.78
Development of individualized anti-metastasis strategies by engineering nanomedicines. Chem Soc Rev (2015) 0.77
Acrolein: unwanted side product or contribution to antiangiogenic properties of metronomic cyclophosphamide therapy? J Cell Mol Med (2008) 0.77
Recent Advance of Biological Molecular Imaging Based on Lanthanide-Doped Upconversion-Luminescent Nanomaterials. Nanomaterials (Basel) (2014) 0.77
Release of membrane-bound vesicles and inhibition of tumor cell adhesion by the peptide Neopetrosiamide A. PLoS One (2010) 0.77
WISP1-αvβ3 integrin signaling positively regulates TLR-triggered inflammation response in sepsis induced lung injury. Sci Rep (2016) 0.76
Comparison between 68Ga-bombesin (68Ga-BZH3) and the cRGD tetramer 68Ga-RGD4 studies in an experimental nude rat model with a neuroendocrine pancreatic tumor cell line. EJNMMI Res (2011) 0.76
Non-invasive assessment of inter-and intrapatient variability of integrin expression in metastasized prostate cancer by PET. Oncotarget (2016) 0.76
The Effect of Stromal Integrin β3-Deficiency on Two Different Tumors in Mice. Cancers (Basel) (2016) 0.75
Multifunctional drug nanocarriers formed by cRGD-conjugated βCD-PAMAM-PEG for targeted cancer therapy. Colloids Surf B Biointerfaces (2015) 0.75
Targeting activated hepatic stellate cells (aHSCs) for liver fibrosis imaging. EJNMMI Res (2015) 0.75
Specific biomarkers of receptors, pathways of inhibition and targeted therapies: pre-clinical developments. Br J Radiol (2011) 0.75
Transarterial administration of integrin inhibitor loaded nanoparticles combined with transarterial chemoembolization for treating hepatocellular carcinoma in a rat model. World J Gastroenterol (2016) 0.75
Molecular imaging in tumor angiogenesis and relevant drug research. Int J Biomed Imaging (2011) 0.75
Multimodality Imaging in Tumor Angiogenesis: Present Status and Perspectives. Int J Mol Sci (2017) 0.75
Evaluation of (99m)Tc-3PRGD2 integrin receptor imaging in hepatocellular carcinoma tumour-bearing mice: comparison with (18)F-FDG metabolic imaging. Ann Nucl Med (2017) 0.75
High-thermoelectric performance of nanostructured bismuth antimony telluride bulk alloys. Science (2008) 7.34
In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol (2006) 6.93
Carbon nanotubes as photoacoustic molecular imaging agents in living mice. Nat Nanotechnol (2008) 6.41
Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett (2006) 5.63
Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc Natl Acad Sci U S A (2008) 4.89
In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation (2006) 4.48
Multimodality molecular imaging of tumor angiogenesis. J Nucl Med (2008) 3.99
Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res (2008) 3.47
US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology (2008) 3.15
microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med (2005) 2.96
Nanoparticle-based theranostic agents. Adv Drug Deliv Rev (2010) 2.86
Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med (2007) 2.86
PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med (2008) 2.77
microPET-based biodistribution of quantum dots in living mice. J Nucl Med (2007) 2.76
Nanoplatforms for targeted molecular imaging in living subjects. Small (2007) 2.69
Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med (2006) 2.65
Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small (2009) 2.59
(64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med (2007) 2.50
PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials (2010) 2.31
Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging (2007) 2.31
PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med (2007) 2.28
PET of vascular endothelial growth factor receptor expression. J Nucl Med (2006) 2.18
In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res (2006) 2.09
Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des (2008) 2.04
Near-infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice. Bioconjug Chem (2005) 2.01
Ultrahigh sensitivity carbon nanotube agents for photoacoustic molecular imaging in living mice. Nano Lett (2010) 2.00
(68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. Eur J Nucl Med Mol Imaging (2008) 1.91
18F-labeled galacto and PEGylated RGD dimers for PET imaging of αvβ3 integrin expression. Mol Imaging Biol (2009) 1.90
Ultrasmall c(RGDyK)-coated Fe3O4 nanoparticles and their specific targeting to integrin alpha(v)beta3-rich tumor cells. J Am Chem Soc (2008) 1.89
Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging. Nat Protoc (2008) 1.87
A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression. J Nucl Med (2006) 1.83
How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther (2006) 1.81
Pulse accumulation, radial heat conduction, and anisotropic thermal conductivity in pump-probe transient thermoreflectance. Rev Sci Instrum (2008) 1.80
64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem (2007) 1.79
Unusual magnetic properties of one-dimensional molecule-based magnets associated with a structural phase transition. Inorg Chem (2002) 1.78
Near-infrared fluorescent deoxyglucose analogue for tumor optical imaging in cell culture and living mice. Bioconjug Chem (2006) 1.75
(68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging. Eur J Nucl Med Mol Imaging (2009) 1.69
Surface-engineered magnetic nanoparticle platforms for cancer imaging and therapy. Acc Chem Res (2011) 1.69
Upconversion nanoparticles: design, nanochemistry, and applications in theranostics. Chem Rev (2014) 1.68
Click chemistry for (18)F-labeling of RGD peptides and microPET imaging of tumor integrin alphavbeta3 expression. Bioconjug Chem (2007) 1.64
Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev (2010) 1.63
Why integrin as a primary target for imaging and therapy. Theranostics (2011) 1.61
High-affinity peptide against MT1-MMP for in vivo tumor imaging. J Control Release (2011) 1.59
Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels. Radiology (2011) 1.59
Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging. Stem Cells (2009) 1.58
Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem (2011) 1.56
Oxorhenium(V) complexes containing tridentate Schiff-base and monothiol coligands. Inorganica Chim Acta (2000) 1.56
Light-triggered theranostics based on photosensitizer-conjugated carbon dots for simultaneous enhanced-fluorescence imaging and photodynamic therapy. Adv Mater (2012) 1.56
Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur J Nucl Med Mol Imaging (2008) 1.55
Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res (2008) 1.49
Characterizing breast cancer xenograft epidermal growth factor receptor expression by using near-infrared optical imaging. Acta Radiol (2009) 1.49
Integrin targeting for tumor optical imaging. Theranostics (2011) 1.47
Effects of nanoparticle size on cellular uptake and liver MRI with polyvinylpyrrolidone-coated iron oxide nanoparticles. ACS Nano (2010) 1.46
microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J Nucl Med (2007) 1.46
Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers. Mol Imaging Biol (2006) 1.46
First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med (2013) 1.44
Photosensitizer-loaded gold vesicles with strong plasmonic coupling effect for imaging-guided photothermal/photodynamic therapy. ACS Nano (2013) 1.44
Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy. Angew Chem Int Ed Engl (2009) 1.44
Peptide-based probes for targeted molecular imaging. Biochemistry (2010) 1.43
A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur J Nucl Med Mol Imaging (2007) 1.43
Triblock copolymer coated iron oxide nanoparticle conjugate for tumor integrin targeting. Biomaterials (2009) 1.42
A strategy for the proliferation of Ulva prolifera, main causative species of green tides, with formation of sporangia by fragmentation. PLoS One (2010) 1.42
Integrin targeted delivery of chemotherapeutics. Theranostics (2011) 1.42
Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers. Mol Pharm (2009) 1.41
Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer. Bioconjug Chem (2007) 1.39
Ultrasmall near-infrared non-cadmium quantum dots for in vivo tumor imaging. Small (2010) 1.38
18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med (2006) 1.37
Protease-activated drug development. Theranostics (2012) 1.36
Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers. Bioconjug Chem (2009) 1.36
PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med (2009) 1.36
Noninvasive imaging of tumor integrin expression using (18)F-labeled RGD dimer peptide with PEG (4) linkers. Eur J Nucl Med Mol Imaging (2009) 1.35
Short hairpin RNA interference therapy for ischemic heart disease. Circulation (2008) 1.34
Dual-modality probes for in vivo molecular imaging. Mol Imaging (2009) 1.34
Unusual magnetic property associated with dimerization within a nickel tetramer. Inorg Chem (2002) 1.33
Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression. Front Biosci (2007) 1.33
Single continuous wave laser induced photodynamic/plasmonic photothermal therapy using photosensitizer-functionalized gold nanostars. Adv Mater (2013) 1.31
Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab. Eur J Nucl Med Mol Imaging (2009) 1.30
Are quantum dots ready for in vivo imaging in human subjects? Nanoscale Res Lett (2007) 1.30
Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res (2010) 1.29
18F-labeled BBN-RGD heterodimer for prostate cancer imaging. J Nucl Med (2008) 1.29
Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer. J Nucl Med (2009) 1.29
Polymeric nanoparticle-based activatable near-infrared nanosensor for protease determination in vivo. Nano Lett (2009) 1.29
Noninvasive de novo imaging of human embryonic stem cell-derived teratoma formation. Cancer Res (2009) 1.28
(68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging (2009) 1.28
18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy. J Nucl Med (2010) 1.28
Real-time video imaging of protease expression in vivo. Theranostics (2011) 1.27
18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma. Eur J Nucl Med Mol Imaging (2011) 1.26
Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Eur J Nucl Med Mol Imaging (2007) 1.26
In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in an orthotopic glioblastoma model. Mol Imaging Biol (2006) 1.26
Limb remote ischemic postconditioning protects against focal ischemia in rats. Brain Res (2009) 1.26
Family of enhanced photoacoustic imaging agents for high-sensitivity and multiplexing studies in living mice. ACS Nano (2012) 1.26
Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J Nucl Med (2007) 1.26
First experience with clinical-grade ([18F]FPP(RGD₂): an automated multi-step radiosynthesis for clinical PET studies. Mol Imaging Biol (2012) 1.26
Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. J Med Chem (2009) 1.26
Delayed postconditioning protects against focal ischemic brain injury in rats. PLoS One (2008) 1.25
Theranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives. Nanoscale (2011) 1.25
PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin-targeted tracer 18F-AlF-NOTA-PRGD2. Eur J Nucl Med Mol Imaging (2012) 1.25
In vivo tumor-targeted fluorescence imaging using near-infrared non-cadmium quantum dots. Bioconjug Chem (2010) 1.24
Chimeric ferritin nanocages for multiple function loading and multimodal imaging. Nano Lett (2011) 1.24
Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imaging (2007) 1.23